2007
October 11, 2017
|By natasa
- Aremed® (Anastrozole), a new generic product to fight breast cancer successfully passed clinical testing and registration begun in the EU and other countries and at the same time Zirex® (Cetirizine), an antihistamine drug, Pizogran® (Pizotifen), an antimigraine drug and Amlorine® (Amlodipine), a calcium channel blocker were registered.
- The company had two more successful inspections: by the Australian Health Authorities (TGA) and by the International Committee of the Red Cross.